Hims & Hers Health logo

Hims & Hers HealthNYSE: HIMS

Profile

Country:

United States

IPO:

13 September 2019

Next earnings report:

04 November 2024

Last dividends:

N/A

Next dividends:

N/A
$4.93 B
-7%vs. 3y high
74%vs. sector
283.75
-2%vs. 3y high
100%vs. sector
-11%vs. 3y high
96%vs. sector
-38%vs. 3y high
92%vs. sector

Price

after hours | 9 min ago
$22.70+$2.20(+10.73%)

Dividend

No data over the past 3 years
$315.65 M$382.20 M
$315.65 M$13.30 M

Analysts recommendations

Institutional Ownership

HIMS Latest News

Markets Temper Enthusiasm Ahead of Election Day
zacks.com04 November 2024 Sentiment: -

We don't expect any sudden movements in the stock market until Wednesday morning the earliest.

Could This Magnificent Pharma Stock 10x in the Next 5 Years?
fool.com30 October 2024 Sentiment: POSITIVE

Disrupting pharmacies is just the start for Hims & Hers.

Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
zacks.com28 October 2024 Sentiment: NEUTRAL

Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Hims & Hers' Incredible Growth Will Continue
fool.com18 October 2024 Sentiment: POSITIVE

GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.

HIMS: GLP-1 Is Just The Beginning
seekingalpha.com17 October 2024 Sentiment: POSITIVE

Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is positioned for high margins and recurring revenues in the growing healthcare market. HIMS achieved positive operating income with 50% revenue growth and 270% EBITDA increase, signaling strong financial health and future potential.

Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
https://www.investopedia.com/hims-and-hers-stock-jumps-as-fda-reconsiders-restrictions-on-copycat-weight-loss-drugs-872791014 October 2024 Sentiment: POSITIVE

Hims & Hers Health (HIMS) shares surged Monday after the Food and Drug Administration (FDA) said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage of their active ingredient.

Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
https://www.businesswire.com/news/home/20241014034535/en/Hims-Hers-to-Announce-Third-Quarter-2024-Financial-Results-on-November-4-2024/14 October 2024 Sentiment: POSITIVE

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter financial results after the market closes on Monday, November 4, 2024. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referenci.

FDA Buzz Sends Health and Wellness Stock Surging
schaeffersresearch.com14 October 2024 Sentiment: POSITIVE

Shares of Hims & Hers Health Inc (NYSE:HIMS) are popping 10% higher to trade at $20.50 this morning, running higher off good news from the Food and Drug Administration (FDA).

Where Does Hims & Hers Stock Go From Here?
fool.com12 October 2024 Sentiment: NEUTRAL

Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?

2 Incredibly Cheap Growth Stocks to Buy Right Now
fool.com12 October 2024 Sentiment: POSITIVE

Look beyond the stock price at the business when shares are volatile.

What type of business is Hims & Hers Health?

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

What sector is Hims & Hers Health in?

Hims & Hers Health is in the Consumer Defensive sector

What industry is Hims & Hers Health in?

Hims & Hers Health is in the Household & Personal Products industry

What country is Hims & Hers Health from?

Hims & Hers Health is headquartered in United States

When did Hims & Hers Health go public?

Hims & Hers Health initial public offering (IPO) was on 13 September 2019

What is Hims & Hers Health website?

https://www.forhims.com

Is Hims & Hers Health in the S&P 500?

No, Hims & Hers Health is not included in the S&P 500 index

Is Hims & Hers Health in the NASDAQ 100?

No, Hims & Hers Health is not included in the NASDAQ 100 index

Is Hims & Hers Health in the Dow Jones?

No, Hims & Hers Health is not included in the Dow Jones index

When was Hims & Hers Health the previous earnings report?

No data

When does Hims & Hers Health earnings report?

The next expected earnings date for Hims & Hers Health is 04 November 2024